The short version of Reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Typical storage | Minus 20 C or below | Lyophilized powder, protected from light |
| Solubility class | Freely soluble in water | Also dissolves in normal saline |
| Identity method | Mass spectrometry | Measured mass compared with calculated value |
| Purity method | Reverse-phase HPLC | Reported as area percentage of main peak |
| Common counterion | Acetate | Salt form varies by supplier and batch |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
In development, the viability of the process on a semi-commercial scale has to be demonstrated. Trial quantities of the new fine chemical have to be manufactured for market development, clinical tests, and other requirements. The necessary data has to be generated in order to enable the engineering department to plan the modifications of the industrial-scale plant and in order to calculate production costs for the expected large-volume requirements. Both equipment and plant layout of the pilot plant reflect those of an industrial multipurpose plant, except for the size of reaction vessels (bench-scale laboratory ~10–60 liters; pilot plant ~100–2500 liters) and the degree of process automation. Before the process is ready for transfer to the industrial-scale plant, the following activities have to be completed: adaptation of the laboratory process to the constraints of a pilot plant, hazard and operability (HAZOP) analysis, and execution of demonstration batches. The main differences between laboratory synthesis and industrial scale production are shown in Table 4.
Trans-sphincteric route into the IAS, Inter-sphincteric route into the IAS, Inter-sphincteric route into the submucosa, Trans-anal injection into the submucosa (similar to injection sclerotherapy for haemorrhoids), Trans-sphincteric route into the inter-sphincteric space, Inter-sphincteric route into the inter-sphincteric space, Trans-sphincteric route injecting submucosally. The perianal injection route (intersphincteric or transsphincteric) gives better results than the transanal route according to one review. Submucosal implant location may have a higher risk of erosion and sepsis.
=== Prescription trends === Between 1998 and 2017, along with imipramine, amitriptyline was the most commonly prescribed first antidepressant for children aged 5–11 years in England. It was also the most prescribed antidepressant (along with fluoxetine) for 12- to 17-year-olds.
Sources: en.wikipedia.org
=== Explosives manufacture === Oleum is used in the manufacture of many explosives with the notable exception of nitrocellulose. (In modern manufacturing of nitrocellulose, the H2SO4 concentration is often adjusted using oleum.) The chemical requirements for explosives manufacture often require anhydrous mixtures containing nitric acid and sulfuric acid. Ordinary commercial grade nitric acid consists of the constant boiling azeotrope of nitric acid and water, and contains 68% nitric acid. Mixtures of ordinary nitric acid in sulfuric acid therefore contain substantial amounts of water and are unsuitable for processes such as those that occur in the manufacture of trinitrotoluene. The synthesis of RDX and certain other explosives does not require oleum. Anhydrous nitric acid, referred to as white fuming nitric acid, can be used to prepare water-free nitration mixtures, and this method is used in laboratory scale operations where the cost of material is not of primary importance. Fuming nitric acid is hazardous to handle and transport, because it is extremely corrosive and volatile. For industrial use, such strong nitration mixtures are prepared by mixing oleum with ordinary commercial nitric acid so that the free sulfur trioxide in the oleum consumes the water in the nitric acid.
Defense against ballistic, hypersonic, advanced cruise missiles, and next-generation aerial attacks Deployment of the Hypersonic and Ballistic Tracking Space Sensor layer Deployment of proliferated space-based interceptors capable of boost-phase intercept Deployment of terminal-phase intercept capabilities to defeat countervalue attacks (Glide Phase Interceptors (GPIs)) Deployment of the Space Development Agency's Proliferated Warfighter Space Architecture custody layer Deployment of capabilities to defeat missile attacks before launch ("left of launch" preemptive strike capabilities) Deployment of a secure supply chain for all components Deployment of non-kinetic capabilities to augment kinetic attacks
=== Other === Some light hydrocarbons are used as aerosol sprays. Alkanes from hexadecane upwards form the most important components of fuel oil and lubricating oil. In the latter function, they work at the same time as anti-corrosive agents, as their hydrophobic nature means that water cannot reach the metal surface. Many solid alkanes find use as paraffin wax, for example, in candles. This should not be confused however with true wax, which consists primarily of esters. Alkanes with a chain length of approximately 35 or more carbon atoms are found in bitumen, used, for example, in road surfacing. However, the higher alkanes have little value and are usually split into lower alkanes by cracking.
Sources: en.wikipedia.org
The founders, who still operate the Clearwater-based company and its 22 restaurants, plan to "de-sexualize" the image of Hooters by making attire slightly more modest, ending bikini nights, and returning to its family friendlier roots, while also improving the food quality and reinvesting into the restaurants. On February 16, 2026, the last Hooters restaurant on Long Island, New York located in Farmingdale closed. On March 22, 2026, the Hooters at Mall of America closed after being at the mall for 33 years. As of August, 2026, the company has indefinitely closed all remaining locations in 4 states: New York, Massachusetts, Connecticut, and Minnesota. There was no prior notice to the public, and no other details other than a piece of paper taped to the inside of the door, reading:
In lichenology, where many genera are small (the average genus has approximately 19 species, and a quarter of genera are monospecific), changes at genus level can particularly cause fragmentation. Discussions continue on how best to balance the need for monophyletic groups with the practical need for taxa that are reasonably diagnosable and useful. Nimis's five‑point checklist, although written for generic splits, provided an early blueprint for balancing lineage evidence with the practical need for taxonomic stability. Emerging technologies offer new tools for lichen systematics. Long-read sequencing is making it feasible to assemble complete genomes of lichen fungi and their photobionts, providing extensive character data and resolving complex structural variants. Environmental metagenomics can detect lichen DNA in soil and air samples, potentially allowing surveys of overlooked microlichen diversity. Machine learning models show promise for identifying lichens from photographs and detecting patterns in multidimensional datasets. However, these technologies require robust reference databases and high-quality baseline taxonomy to be effective. As Lücking (2020) notes, incomplete or flawed taxonomy will simply be perpetuated more rapidly by automated systems. The principle of the "minimum adequate method" remains relevant—traditional methods like culture experiments and careful morphological observation continue to answer questions that sequencing alone cannot.
This name was officially adopted by the International Union of Pure and Applied Chemistry (IUPAC) in 1949, becoming the second element after gallium to be named after France. It was assigned the symbol Fa, but it was revised to the current Fr shortly thereafter. Francium was the last element discovered in nature, rather than synthesized, following hafnium and rhenium. Further research into francium's structure was carried out by, among others, Sylvain Lieberman and his team at CERN in the 1970s and 1980s.
In 1979, a possible association between autism and opioids was proposed, it was noted that injecting small amounts of opiates into young laboratory animals resulted in symptoms similar to those seen in autistic children. The possibility of a relationship between autism and the consumption of gluten and casein was first articulated by Kalle Reichelt in 1991. Opiate theory hypothesizes that autism is the result of a metabolic disorder in which opioid peptides gliadorphin (aka gluteomorphin) and Casomorphin, produced through metabolism of gluten (present in wheat and related cereals) and casein (present in dairy products), pass through an abnormally permeable intestinal wall and then proceed to exert an effect on neurotransmission through binding with opioid receptors. It has been postulated that the resulting excess of opioids affects brain maturation and causes autistic symptoms including: behavioral difficulties, attention problems, and alterations in communicative capacity and social and cognitive functioning. Although high levels of these opioids are eliminated in the urine, it has been suggested that a small part of them cross into the brain causing interference of signal transmission and disruption of normal activity. Three studies have reported that urine samples of people with autism show an increased 24-hour peptide excretion. A study with a control group found no appreciable differences in opioid levels in urine samples of people with autism compared to controls. Two studies showed an increased opioid levels in cerebrospinal fluid of people with autism.
Sources: en.wikipedia.org
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.
Cold storage at minus twenty degrees Celsius or below is the common recommendation for the lyophilized powder, together with protection from light and moisture. Dissolved material is generally treated as less stable and is handled cold with short working windows.
A useful certificate lists the analytical method used, the measured purity, the mass determined by spectrometry, and the storage conditions. Independent verification from a second laboratory is sometimes requested, since supplier-issued documents are not always produced in the same facility as the material.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.